124 related articles for article (PubMed ID: 38619967)
21. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation.
Park A; Lee Y; Kim MS; Kang YJ; Park YJ; Jung H; Kim TD; Lee HG; Choi I; Yoon SR
Front Immunol; 2018; 9():1859. PubMed ID: 30140269
[TBL] [Abstract][Full Text] [Related]
23. Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a.
Grauwet K; Vitale M; De Pelsmaeker S; Jacob T; Laval K; Moretta L; Parodi M; Parolini S; Cantoni C; Favoreel HW
J Virol; 2016 Feb; 90(3):1522-33. PubMed ID: 26581992
[TBL] [Abstract][Full Text] [Related]
24. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.
Dufva O; Gandolfi S; Huuhtanen J; Dashevsky O; Duàn H; Saeed K; Klievink J; Nygren P; Bouhlal J; Lahtela J; Näätänen A; Ghimire BR; Hannunen T; Ellonen P; Lähteenmäki H; Rumm P; Theodoropoulos J; Laajala E; Härkönen J; Pölönen P; Heinäniemi M; Hollmén M; Yamano S; Shirasaki R; Barbie DA; Roth JA; Romee R; Sheffer M; Lähdesmäki H; Lee DA; De Matos Simoes R; Kankainen M; Mitsiades CS; Mustjoki S
Immunity; 2023 Dec; 56(12):2816-2835.e13. PubMed ID: 38091953
[TBL] [Abstract][Full Text] [Related]
25. Chemo-enzymatic modification of poly-N-acetyllactosamine (LacNAc) oligomers and N,N-diacetyllactosamine (LacDiNAc) based on galactose oxidase treatment.
Kupper CE; Rosencrantz RR; Henßen B; Pelantová H; Thönes S; Drozdová A; Křen V; Elling L
Beilstein J Org Chem; 2012; 8():712-25. PubMed ID: 23015818
[TBL] [Abstract][Full Text] [Related]
26. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
27. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
28. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
29. KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.
Blunt MD; Vallejo Pulido A; Fisher JG; Graham LV; Doyle ADP; Fulton R; Carter MJ; Polak M; Johnson PWM; Cragg MS; Forconi F; Khakoo SI
J Immunol; 2022 Jul; 209(2):379-390. PubMed ID: 35768150
[TBL] [Abstract][Full Text] [Related]
30. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
[TBL] [Abstract][Full Text] [Related]
32. Preferential expression of sialyl 6'-sulfo N-acetyllactosamine-capped O-glycans on high endothelial venules in human peripheral lymph nodes.
Tsutsumiuchi M; Hoshino H; Kogami A; Tsutsumiuchi T; Yokoyama O; Akama TO; Kobayashi M
Lab Invest; 2019 Oct; 99(10):1428-1441. PubMed ID: 31148596
[TBL] [Abstract][Full Text] [Related]
33. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
34. Endogenous tagging reveals a mid-Golgi localization of the glycosyltransferase-cleaving intramembrane protease SPPL3.
Truberg J; Hobohm L; Jochimsen A; Desel C; Schweizer M; Voss M
Biochim Biophys Acta Mol Cell Res; 2022 Nov; 1869(11):119345. PubMed ID: 36007678
[TBL] [Abstract][Full Text] [Related]
35. Poly-LacNAc as an age-specific ligand for rotavirus P[11] in neonates and infants.
Liu Y; Huang P; Jiang B; Tan M; Morrow AL; Jiang X
PLoS One; 2013; 8(11):e78113. PubMed ID: 24244290
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
37. CRISPR Screen to Identify Factors that Render Tumor Cells Sensitive or Resistant to Killing by NK Cells.
Zhuang X; Long EO
Methods Mol Biol; 2022; 2463():269-288. PubMed ID: 35344181
[TBL] [Abstract][Full Text] [Related]
38.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
39. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Watters JM; Wright G; Smith MA; Shah B; Wright KL
Biochem Biophys Res Commun; 2021 Jan; 534():773-779. PubMed ID: 33190829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
